Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.27: L-lactate dehydrogenase

This is an abbreviated version!
For detailed information about L-lactate dehydrogenase, go to the full flat file.

Word Map on EC 1.1.1.27

Reaction

(S)-lactate
+
NAD+
=
pyruvate
 +
NADH
 +
H+

Synonyms

A4-LDH, AdhE, alpha-HBDH, alpha-hydroxybutyrate dehydrogenase, anaerobic lactate dehydrogenase, BbLDH, dehydrogenase, lactate, eLDHA, eLDHB, Epsilon crystallin, epsilon-crystallin, H4-L-lactate dehydrogenase, HBDH, heart LDH, Immunogenic protein p36, L(+)-nLDH, L-(+)-lactate dehydrogenase, L-lactate dehydrogenase, L-lactate dehydrogenase B, L-lactic acid dehydrogenase, L-lactic dehydrogenase, L-LDH, L-Ldh0845, L-nLDH, lactate dehydrogenase, lactate dehydrogenase 5, lactate dehydrogenase A, lactate dehydrogenase B, lactate dehydrogenase NAD-dependent, lactic acid dehydrogenase, lactic dehydrogenase, LctD, LDH, LDH-1, LDH-2, LDH-3, LDH-4, LDH-5, LDH-A, LDH-A4, LDH-m4, LDH1, LDH2, LdhA, LDHB, ldhL, LDHL1, LDHL2, LOX, LutACB, mL-LDH, mLDH, More, muscle LDH, NAD-dependent lactate dehydrogenase, NAD-lactate dehydrogenase, NGO0904, NGO0905, NGO0906, nitric oxideinducible l-lactate dehydrogenase, PfLDH, proteins, specific or class, anoxic stress response, p34, Sa-LDH-1, SMU.1115, SMU_1115, TeLdhL, Tsac_0416

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.27 L-lactate dehydrogenase

Inhibitors

Inhibitors on EC 1.1.1.27 - L-lactate dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(abieta-8,11,13-trien-18-ylamino)(oxo)acetic acid
(benzylamino)(oxo)acetic acid
(heptylamino)(oxo)acetic acid
(hexylamino)(oxo)acetic acid
(nonylamino)(oxo)acetic acid
([2-cyano-4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]-2-methoxyphenyl]amino)(oxo)acetic acid
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
1,6-dibromo-2-hydroxynaphthalene 3-carboxylic acid
-
0.31 mM
1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indol-2-carboxylic acid
a N-hydroxyindole, NH1-1, and a competitive inhibitor with respect to both NADH and pyruvate
1-[7-[3,4-dihydroxy-2-imino-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-8-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalen-1-yl]ethanone
2,3-dihydroxy-4,6,7-trimethylnaphthalene-1-carboxylic acid
2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6,7-dimethyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6,7-dimethyl-4-propylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-(propan-2-yl)-7-[4-(trifluoromethyl)benzyl]naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(2-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(3-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(4-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,6-naphthalene disulfonic acid
-
IC50: 21 mM
2,6-naphthalenedicarboxalic acid
-
IC50: 5.1 mM
2-mercaptoethanol
10% inhibition at 1 mM
3,5-dihydroxy 2-naphthoic acid
-
IC50: 1.7 mM
3,5-dihydroxynaphthalene-2-carboxylic acid
3,7-dihydroxy naphthalene-2-carboxylic acid
-
IC50: 2.4 mM
3,7-dihydroxynaphthalene-2-carboxylic acid
3-((3-carbamoyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinolin-4-yl) amino) benzoic acid
a quinoline-3-sulfonamide, competitive inhibitor with respect to both NADH and pyruvate
3-(3-nitro-4-pyridyl)pyruvate
-
-
3-(3-nitropyridin-4-yl)-2-oxopropanoic acid
-
-
3-([3-carbamoyldimethoxypyrimidin-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino)benzoic acid
enzyme binding structure, overview
3-acetylpyridine adenine dinucleotide
-
the enzyme exhibits characteristic reduced substrate inhibition and enhanced kcat
3-Aminopyridine adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
3-Fluoropyruvate
-
-
3-hydroxy-1,2-oxazole-4-carboxylic acid
-
-
3-hydroxy-1-oxaspiro[4.5]dec-3-en-2-one
-
-
3-hydroxy-2-oxo-1-oxaspiro[4,5]-dec-3-ene
-
-
3-nitropropionate
-
-
3-phosphoglycerate
-
-
3-[7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl]aminobenzoic acid
enzyme binding structure, overview
4,7-dibromo-3-hydroxynaphthalene-2-carboxylic acid
4-(ethylcarbamoyl)benzoic acid
4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid
-
-
4-hydroxy-1,2-oxazole-3-carboxylic acid
-
-
6,6'-disulfanediyldipyridine-3-carboxylic acid
6,6'-Dithiodinicotinic acid
-
IC50: 6.6 mM
6-benzyl-3,4-dihydroxy-7-methyl-1-propylnaphthalene-2-carboxylic acid
FX11, a competitive inhibitor with respect to both NADH and pyruvate
6-phosphogluconate
-
-
7-(4-chlorobenzyl)-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
8'-acetyl-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8-carboxylic acid
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl acetate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl butanoate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl pentanoate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl propanoate
8-(2-[4-[(carboxycarbonyl)amino]-3-methoxyphenyl]ethoxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
8-(phenylamino)naphthalene-1-sulfonic acid
8-([4-[(carboxycarbonyl)amino]-3-methoxybenzyl]oxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
8-anilino-1-naphthalene sulfonic acid
-
IC50: 0.52 mM
8-[8-acetyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-3,4-dihydroxy-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-2-one
Alpha-NAD+
-
noncompetitive inhibitor versus beta-NAD+
amino(oxo)acetic acid
ascorbate
-
at concentrations normally found in tissue. It is proposed that ascorbate facilitates the storage of glycogen in muscle at rest by inhibiting glycolysis. Aldolase and muscle G-actin protect and reverse inhibition
AZ-33
a malonic derivative, a competitive inhibitor with respect to both NADH and pyruvate
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')copper
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')zinc
cardiolipin
-
IC50: 0.00005 mM, interaction with acidic phospholipids is most efficient at pH values below pH 6.5
Chinese gall
ethanol extract of the Chinese gall, commonly named Wu Bei Zi, strongly inhibits the enzyme
-
Chloroquine
citrate
-
-
citrate/phosphate buffer
-
at pH 5.4
Cu[Ac]2[2,2'-bipyridine]
-
analysis of interaction with the LDH isozymes and their modulation, significantly inhibits LDH in liver, kidney, heart, spleen, brain and skeletal muscle tissues, overview
D-fructose 1,6-bisphosphate
D-fructose-1,6-diphosphate
-
5 mM, 25% loss of activity
D-lactate
-
dead-end inhibitor, competitive inhibitor versus L-lactate
dicholesteroyl diselenide
-
inhibition of different isoforms of lactate dehydrogenase by dicholesteroyl diselenide possibly involves the modification of the thiol groups at the NAD+ binding site of the enzyme. Exerts profound concentration dependent inhibitory effect on the activity of renal LDH. Inhibitory effect on hepatic LDH is markedly pronounced at 2, 4, 8 and 10 microM. Strongly inhibits cardiac LDH activity when NAD+ is omitted from the pre-incubating medium than when lactate is absent from the pre-incubating medium, significantly inhibits the enzyme activity at 1, 2, 4, and 8 microM
dihydroxyacetone phosphate
-
-
diphenyl diselenide
-
inhibition of different isoforms of lactate dehydrogenase by diphenyl diselenide possibly involves the modification of the thiol groups at the NAD+ binding site of the enzyme. Inhibitory effect on hepatic LDH is markedly different at 10 microM. Markedly inhibits cardiac LDH activity at 8 and 10 microM
DTT
19% inhibition at 1 mM
epigallocatechin
the most potent compound with anti-LDH-5 activity under both normoxia and hypoxia conditions
ethyl 3-(3-cyano-4-pyridyl)pyruvate
-
-
ethyl 3-(3-cyanopyridin-4-yl)-2-oxopropanoate
-
-
Fe3+
complete inhibition at 1 mM
fructose 1,6-bisphosphate
fructose 1,6-diphosphate
galloflavin
a blocker of LDH-5-ssDNA interactions, preventing RNA synthesis
glucose 6-phosphate
-
-
glutamate
Agama stellio stellio
-
both directions
GNE-140
a piperidine derivative LDH-5 inhibitor
gossylic nitrile 1,1'-diacetate
gossypol
gossypol lactone
GSK 2837808A
-
-
HEPES buffer
-
-
hydroxychloroquine
-
iodoacetamide
iodoacetate
isocitrate
-
-
L-lactate
Lactate
-
a high concentration of lactate has a weak inhibitory effect on the pyruvate reduction reaction activity but is meaningful for a significant lactate oxidation rate as the K m value of LDHA for L-lactate is very high
Lactate analogs
-
-
-
methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indol-2-carboxylate
a N-hydroxyindole, NH1-2, and a competitive inhibitor with respect to both NADH and pyruvate
methylmalonate
NaCl
-
2 M, 36% loss of activity
NADH
-
competitive with respect to NAD+
naphthalene-2,6-dicarboxylic acid
naphthalene-2,6-disulfonic acid
nicotinic acid adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
o-phthalaldehyde
-
modification not only results in inactivation of the enzyme, but also leads to the enzyme‘s dissociation and partial unfolding
oxalate
oxaloacetate
oxamate
oxo(pentadecylamino)acetic acid
oxo(phenylamino)acetic acid
oxo[(2-phenylethyl)amino]acetic acid
oxo[(2-phenylpropyl)amino]acetic acid
oxo[(3-phenylpropyl)amino]acetic acid
oxo[(4-phenylbutan-2-yl)amino]acetic acid
oxo[(4-phenylbutyl)amino]acetic acid
oxo[(tetrahydrofuran-2-ylmethyl)amino]acetic acid
oxo[[1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl]amino]acetic acid
p-chloromercuribenzoate
p-hydroxymercuribenzoate
Phenylglyoxal
-
-
phosphate
phosphatidylserine
-
IC50: 0.0013 mM, interaction with acidic phospholipids is most efficient at pH values below pH 6.5
phosphoenolpyruvate
pyruvate
SDS
complete inhibition at 0.1%
Sodium oxamate
-
-
Sodium phosphate
-
-
Spatholobus suberectus extract
the extract has a strong inhibitory effect on LDH-5 expression and activity inboth estrogen-dependent and estrogen-independent human breast cancer cells
-
Tartronate
-
dead-end inhibitor, competitive inhibitor versus L-lactate
Thionicotinamide adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
Tris/maleate buffer
-
at pH 5.4
Urea
-
enzyme activity and electrophoretic pattern of LDH-A4 and malate dehydrogenase, EC 1.1.1.37, compared in relation to heat and urea inactivation, LDH is more sensitive than MDH, overview
Zn[Ac]2[2,2'-bipyridine]
-
analysis of interaction with the LDH isozymes and their modulation, significantly inhibits LDH in liver, kidney, and heart, but not in spleen, brain and skeletal muscle tissues, overview
[(2-ethylphenyl)(phenyl)amino](oxo)acetic acid
[(2-methoxyethyl)amino](oxo)acetic acid
[(3,3-diphenylpropyl)amino](oxo)acetic acid
[(3-methoxypropyl)amino](oxo)acetic acid
[(3-methylbutyl)amino](oxo)acetic acid
[(3-methylphenyl)(phenyl)amino](oxo)acetic acid
[(4-chlorobenzyl)amino](oxo)acetic acid
[(4-methylbenzyl)amino](oxo)acetic acid
[(furan-2-ylmethyl)(methyl)amino](oxo)acetic acid
[(naphthalen-1-ylmethyl)amino](oxo)acetic acid
[benzyl(methyl)amino](oxo)acetic acid
[bis(2-methylpiperidin-1-yl)amino](oxo)acetic acid
[bis(4-benzylpiperazin-1-yl)amino](oxo)acetic acid
[bis(4-benzylpiperidin-1-yl)amino](oxo)acetic acid
[bis(4-phenylpiperazin-1-yl)amino](oxo)acetic acid
[[2-(4-bromophenyl)ethyl]amino](oxo)acetic acid
additional information
-